A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer

In this Clinical Care Options Oncology podcast, Drs. Rachel Grisham and Kathleen Moore discuss the challenges and recent advancements in treating KRAS-mutated low-grade serous ovarian cancer. They highlight the unique molecular characteristics of this cancer type, distinguishing it from high-grade serous ovarian cancer, and emphasize the significance of the FDA-approved combination therapy of avutumetanib and defactinib. The discussion covers the RAMP 201 study, which led to the approval, and the ongoing RAMP 301 phase 3 study. They also address practical considerations such as dosing schedules, toxicity management, and the importance of tissue-based somatic testing for KRAS mutations, while also exploring future directions, including frontline treatment strategies and studies in other KRAS-mutated cancers.